Italia markets close in 1 hour 51 minutes

FATE May 2024 12.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,11000,0000 (0,00%)
In data: 10:10AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,1100
Aperto0,1100
Denaro0,0000
Lettera0,0000
Prezzo d'esercizio12,50
Scadenza2024-05-17
Min-Max giorno0,1100 - 0,1100
Contratto - Min-MaxN/D
Volume1
Open Interest14
  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming September Investor Conferences

    SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 18th Annual BioPharma Conference on Thursday, September 7

  • GlobeNewswire

    Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

    Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-targeted CAR T-cell Program Incorporates Seven Novel Synthetic Controls Designed to Overcome Unique Challenges in Treating Solid Tumors Dose Escalation Ongoing in Phase 1 Studies of FT819 CD19-targeted 1XX CAR T-

  • GlobeNewswire

    Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

    SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 fin